CLOSING BELL

The market cooled off Friday after its record-high run, the tech train leaving the Beijing station and returning to the U.S.

While they were out getting deals done, the market was climbing, the S&P 500 hitting records at 7,517 Thursday. The president’s insane 3,700 trades his office disclosed exemplified the flying-off-the-shelves tech market.

Turns out, the deals were not all that good: Nvidia might not be getting its chips, according to the White House, and Boeing stock is falling after it got word of half the plane sales traders wanted. The 30-year Treasury yield topped 5.1, the 10-year was up 5% this week, each the highest in a year. Inflation data from CPI to PPI sent yields up, showing consumer prices were chasing tech prices at records not seen for years.

On Friday, Stocktwits retail was still anchored by major names like Nvidia and silver ETFs, but the actual post-level conversation was mid-cap heavy, with $CADL and $POET getting the most passionate user engagement.

Today’s Briefing:

• Stocks: POET’s $400M raise split bulls between validation and dilution

• Stocks: Nvidia slid after the Trump-Xi summit delivered no chip thaw

• Macro News: Global yields spiked as oil, inflation, and Fed hike risk hit the tape, Silver became the stress-test trade for inflation hedges

• Biotech: Candel’s prostate cancer data kept Stocktwits bulls engaged

• Pops and Drops & More

STOCKS
POET Financing Fight 🔦

POET Technologies, the optical-interconnect and photonics company tied to AI infrastructure demand, sank Friday after a quarterly loss collided with a giant financing package. Traders had to decide whether the raise validates the ramp or buries the story in dilution. The firm also announced CFO Thomas Mika would retire this year.

The RIP: $POET ( ▼ 22.36% ) fell -22%. Q1 net loss was $12.3M, or $0.08 per share, versus $6.3M profit a year ago. Revenue roughly tripled to $503k. POET raised $400M at $21 per share, with warrants at $26.15.

Stocktwits stayed extremely bullish across 27.6k watchers, with high message volume focused on the $400M raise, customer ramps, and dilution risk. The news followed the massive selloff after the firm’s CFO broke news about the Marvell supply deal.

Trending posts:

• @tkr: “$POET you think $25 was the high. Wait for it as next week we will be in the $40’s” (post)

• @RickFox: “$POET CFO replacement will be interesting. Also bet we buy globetronics, and manufacturing goes into hyper gr…” (post)

The bull case is that institutional capital funds manufacturing, acquisitions, and R&D scale. The bear case is that POET still has to prove revenue can catch up to the share count. 🔦

Bring it to $POET: validation or dilution →

Nvidia China Chill 🧠

Nvidia, the AI chip leader powering the data center buildout, slid Friday after the Trump-Xi summit ended without the chip breakthrough investors wanted. Jensen Huang’s spot in the delegation raised hopes for China sales relief, but the meeting delivered no clear path forward.

The RIP: $NVDA ( ▼ 4.42% ) fell -4.42% to $225.32. Stocktwits showed 645.7k watchers, extremely bullish sentiment at 82/18, and high message volume ahead of next week’s earnings.

Trending posts:

• @KABStockOptionCommunity: “$NVDA gap closed. The day before green candle volume is higher than today’s red candle, which is bullish. We…” (post)

• @Acho5280: “$NVDA Momentum still intact and bulls are clearly in control. This pullback into support didn’t break structu…” (post)

The immediate risk is that China stays locked behind policy friction even after Washington approves H200 exports. Bulls are still leaning on earnings, AI demand, and dip-buying support, but bears finally have two pressure points at once: no China thaw and higher yields squeezing AI multiples. 🧠

Check the tape on $NVDA: China or choke →

SPONSORED BY iHERB
The Logistics of Longevity

In the world of investing, asset management is key. The same rules apply to your health.

While general marketplaces rely on unverified third-party sellers, iHerb – the specialty store for health and wellness – treats its inventory differently. We buy directly from manufacturers and store every product in temperature-controlled fulfillment centers to ensure potency and authenticity. 

Now, that standard is scaling up: iHerb has officially acquired Vitacost, uniting two respected, industry titans to dominate the global wellness market.

• Always Authentic: Direct sourcing, with no third-party sellers.

• Preserved Freshness: Climate-controlled storage

• Global Reach: Shipping to 180+ countries.

Don’t settle for mystery supplements. Invest in a source you can trust.

Shop iHerb

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

TRENDING STOCKS
Pops & Drops

• $TRT ( ▲ 43.01% )  Trio-Tech ⚡: ripped +49% after AI testing squeeze kept running

• $SEDG ( ▲ 22.93% )  SolarEdge ⚡: soared +22% after Q1 revenue topped estimates

• $TNXP ( ▲ 11.71% )  Tonix ⚡: jumped +10% after fibromyalgia approval chatter reignited

• $VG ( ▲ 9.38% )  Venture Global ⚡: surged +9% after EBITDA guidance more than doubled

• $MSFT ( ▲ 3.05% )  Microsoft: popped +3% after Ackman disclosed a new stake

• $RILY ( ▼ 3.53% )  B. Riley ⚡: slid -3% after short-interest pressure stayed elevated

• $CAT ( ▼ 3.47% )  Caterpillar: fell -3% after insider-sale pressure hit sentiment

• $NVDA ( ▼ 4.42% )  Nvidia ⚡: dropped -5% after yields pressured AI-chip leaders

• $QXO ( ▼ 6.31% )  QXO ⚡: slid -6% after dilution worries hit deal sentiment

Yields Bite Back 🧨

The global bond selloff got nastier Friday as rising oil prices, hot inflation data, and no Iran breakthrough pushed traders toward a nastier question: what if the next central bank move is a hike, not a cut? Long-dated bonds took the hit first, and stocks finally felt the valuation math tighten.

The RIP: The U.S. 10-year yield rose 12 bps to 4.6%. The 30-year Treasury neared its 2023 peak. Japan’s 30-year yield hit 4% for the first time since issuance began in 1999. The U.K. 10-year gilt yield jumped to 5.17%, its highest since 2008.

“Markets are starting to price the Fed having to work harder to tamp down inflation,” Ed Al-Hussainy, portfolio manager at Columbia Threadneedle Investments, said Friday.

The equity rally kept treating hot inflation like background noise until the bond market started doing the Fed’s work for it. Rising crude, a still-stuck Iran war, and back-to-back hot CPI and PPI prints make the cut trade harder to defend, especially with swaps leaning toward hikes again.

Silver Catches Macro Bid 🪙

iShares Silver Trust, the ETF tracking physical silver prices, became a macro stress proxy Friday as global bond yields ripped higher and traders debated whether metals benefit from inflation pressure or break with risk assets. The $SLV ( ▼ 8.57% ) stream focused on bond yields, demand, and inflation stress. 🪙

Trending posts:

• @RealtorKK: “$SLV Seriously silver needs a pill to stay hard daily .. gosh takes a month to go up $10 and then loose all i…” (post)

• @Beowulfdragonslayer: “$SLV 60 dollar silver is an impossibility. Better buy now while its on sale. You will never see $75 dollar si…” (post)

Weigh in on $SLV: hedge or break →

Candel Data Heat 🧬

Candel Therapeutics, the cancer immunotherapy developer behind CAN-2409, slipped Friday even after extended Phase 3 prostate cancer data gave bulls more to work with. The stock’s problem was not a lack of data, it was whether traders had already priced in the AUA excitement.

The RIP: $CADL ( ▼ 1.57% ) fell -1.57% to $8.77. Phase 3 follow-up showed 39% improvement in prostate cancer-specific Stocktwits community was bullish, message volume was high across ~9.5K watchers.

Trending posts:

• @PaulNipkow: “$CADL Have seen this movie before ..perfect results aren’t immediately understood by the market. It often tak…” (post)

• @strategicmind: “$CADL mgmt has posted a lot about this event. I think it will be a great update on the data” (post)

The bull case is that Candel may have the first new localized prostate cancer therapy in over 20 years. The bear case is that FDA timing, cash runway, and small-cap biotech volatility still matter before approval. 🧬

Check the tape on $CADL: data or drift →

Chat, Are We Cooked? 🔥 

Is AI in a bubble? Kevin Dubriske, from the bullishbears community, spoke with me at the Cashtag awards just last week, and said he is cautiously optimistic that the market is looking for the right price in an insane new normal.

Check out the interview on Stocktwits, and give your take →

EDITOR’S PICKS
Links That Don’t Suck 🌐

📈 Get data-driven investing insights and our biggest IBD Digital discount of the year––over $200 off*

🤑  Stephen Miran exits the Fed. How he set the stage for Kevin Warsh.

😨 Traders now see next Fed interest rate move as a hike following inflation surge

🏠️ SpaceX reportedly plans to IPO in mid-June, chooses to list on Nasdaq

💰️ Trump’s More Than 3,700 Trades Astonish Wall Street Insiders

📺️ Buffett Steps Aside: Abel’s First Berkshire 13F Buys Delta Air Lines, Exits Visa And Mastercard

👀 Trump Says China Has Not Approved NVDA H200 Chip Purchases Yet — ‘They Want To Develop Their Own’

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here. 

Get In Touch 📬

Want to see some change? Email Kevin Travers feedback, follow him on Stocktwits.

Terms & Conditions 📝

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The content is to be used for informational and entertainment purposes only and the service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which content is published on the service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍
Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋